Our LatestBlog & News

    Marketing Specialist - REMOTE/WFH   DescriptionThe Marketing Specialist will support, improve, and implement technologies, systems, and processes for generating inbound...
      Subtle progressive changes in speech motor function and cognition begin prior to diagnosis of Huntington's disease (HD). Scientists at University...
        Face to face singing therapy can improve speech in PD. Have a look at our previous work published in Neurorehabilitation...
          Rare genetically inherited neurodevelopmental disorders remain a huge diagnostic and therapeutic challenge in clinical medicine. Redenlab pediatric consultant Prof Angela...

            Dr Garcia joins the Redenlab science team to drive its language analytics pipeline for cognitive-linguistic disorders like fronto-temporal dementia.

              Atypical development of Broca’s area in a large family with inherited stuttering Stuttering (aka Stammering) is a neuro-motor disorder of...
                We’re a speech science organisation focused on advancing the development of new treatments and enabling earlier clinical insights in healthcare....

                  Redenlab’s latest iOS application provides state of the art audio capture, storage and analysis of speech and language data for monitoring brain health.

                    Redenlab is contributing to a study sponsored by the Australian Department of Defence and The University of Melbourne on speech biometrics and decision making in submariners

                      Dr Amir Lahav hired as Chief of Digital Health and Strategy. He is a clinical neuroscientist and a leading innovator in digital health with a special focus on developing and validating novel biomarkers and AI-driven technology for remote monitoring of patients with neurodegenerative diseases.

                        Redenlab are presenting some of their work on Parkinson’s Disease and speech at the upcoming virtual Movement Disorders Society Conference...
                          Over the past two decades, genomic studies have played an increasingly important role in exploring the history of our own...
                            The Position Redenlab is seeking an experienced Quality Assurance Associate to join our growing Regulatory Affairs & Quality Assurance Team....

                              Dr Geoff Stuart joins the Redenlab analytics team as Statistics Director. Geoff will be running the company’s clinical trials statistics program and data analytics development. He brings expertise in mathematical statistics and a background in experimental psychology.

                                Redenlab are part of a successful consortium securing funding for training a new cohort of early career researchers in understanding key issues in optimal ageing (including environmental, social and economic factors that underlie health and independence in ageing).

                                  Redenlab Inc. are pleased to announce securing clinical trial in Cyclic Vomiting Syndrome with a Top 10 pharma company. Redenlab are providing audio capture and analytics for a Phase 1b clinical trial. Conducted in sites across the USA, the study will investigate the long-term efficacy of a treatment designed to ameliorate the impact of this rare and debilitating disease.

                                    Professor Angela Morgan has been recognised for her outstanding leadership in advancing the diagnosis, prognosis and management of childhood speech disorders.

                                      Redenlab CSO, Adam Vogel, will be presenting at the upcoming ERN-RND joint webinar with the European Acadamy of Neurology and ERN EURO-NMD: Speech as a biomarker in Ataxia: What can it tell us & how should we use it?

                                        The Position Redenlab is seeking an experienced Software Developer. Redenlab is one of the world’s leading providers of speech and...
                                          Redenlab CSO, Adam Vogel, will be presenting at the upcoming joint webinar with the European Reference Network for rare or...

                                            SpeechATAXIA is a multi-language, multi-national, multi-ataxia consortia designed to measure communication change over time.

                                              Redenlab are proud to support an upcoming randomized parallel group, placebo-controlled, dose-escalation clinical trial in Ataxia Telangiectasia

                                                Welcome Dr Noffs. Gustavo brings a wealth of clinical and research experience to the team, making contributions to tech development and science promotion, with a focus on his specialties of Parkinson’s disease and Multiple Sclerosis.

                                                  Redenlab’s Chief Science Officer (Prof Adam Vogel) presents at the symposia on Facial and Vocal Markers of CNS function, “Speech...

                                                    Redenlab Inc. are excited to announce securing another clinical trial in Friedreich ataxia. Redenlab are providing speech analytics for a long-term open label extension clinical trial. Conducted in 8 sites across the USA over 2 years, the study will investigate the long-term efficacy of a treatment designed to ameliorate the debilitating impact of this fatal disease. For the study, Redenlab will provide advanced speech recording and analysis solutions.

                                                      Redenlab Inc, the speech neuroscience company delivering insights in speech and language testing, announces that it has been selected by medium sized USA pharmaceutical company to support their upcoming gene therapy study in Friedreich ataxia (FA). Conducted across 5 sites in 3 countries over 2 years, the Phase 2a study will investigate the safety, tolerability and efficacy of gene therapy on adolescents with FA. For the study, Redenlab will provide advanced speech recording and analysis solutions.

                                                        Redenlab Inc, the speech neuroscience company delivering insights in communication testing, announces that it has been selected by USA and...

                                                          Redenlab are glad to be supporting Larimar Therapeutics Inc. Phase 1 SAD clinical trial is a double-blind, placebo-controlled, randomized clinical trial to assess the safety of subcutaneously administered CTI-1601 versus placebo in adult subjects with Friedreich Ataxia.

                                                            Redenlab are proud to be supporting PTC Therapeutics, Inc. Global Phase 3 Clinical Trial to Evaluate Vatiquinone in Friedreich Ataxia.

                                                              Learn more about the platforms and applications that Redenlab use for software development, documentation, and quality management that is in-line with standards such as FDA 21 CFR Part 22.

                                                                We are excited to announce that Redenlab Speech Scientists ranked top 1 AND 2 in the world for dysarthria (most common neuromuscular speech disorder)!

                                                                  SCA Global is a worldwide initiative for clinical research in spinocerebellar ataxias. Redenlab founder Adam Vogel will be presenting “Speech...
                                                                    Background & Motivation• Digital Endpoints/Biomarkers based on mobile devices and sensor technology are currentlybeing investigated in many clinical studies• Data...

                                                                      Redenlab has entered into a 5 year collaboration with investigators from North and South America, Australia and Europe to investigate the underlying neural mechanisms of Friedreich ataxia. The study is supported by the Friedreich's Ataxia Research Alliance (FARA) and pharmaceutical industry partners.

                                                                        Describing the relationship between disease severity and speech metrics, through listener-based and objective acoustic analysis.

                                                                          In our new study, published in the Journal of Acoustical Society of America, we tested reliability, stability, and sensitivity to change in vowel measurements.

                                                                            The Huntington Study Group is taking the early and proactive step of moving this year’s annual meeting, HSG 2020: HD...